Business
Bioretec Appoints Dr. Christopher W. DiGiovanni to Scientific Advisory Board
Bioretec Ltd., a pioneer in bioresorbable orthopedic implants, today announced the appointment of Dr. Christopher W. DiGiovanni to its Scientific Advisory Board (SAB).
About this update from Bioretec Ltd.
[{"type":"text","content":"Bioretec Ltd Press Release 4 September 2025 at 3 p.m. EET","length":67,"tagName":"p"},{"type":"text","content":"TAMPERE, Finland, Sept. 4, 2025 /PRNewswire/ -- Bioretec Ltd., a pioneer in bioresorbable orthopedic implants, today announced the appointment of Dr. Christopher W. DiGiovanni to its Scientific Advisory Board (SAB).","length":215,"tagName":"p"},{"type":"text","content":"Dr. DiGiovanni is an internationally recognized foot and ankle surgeon who has dedicated nearly three decades to advancing clinical care, surgical innovation, and medical education. He currently serves as Professor of Orthopaedic Surgery at Harvard Medical School in the Department of Orthopaedic Surgery and Chief Emeritus of Foot and Ankle Services at Massachusetts General Hospital (MGH) / Newton-Wellesley Foot & Ankle Center. He is a Past President of both the American Orthopaedic Foot and Ankle Society and the North American Orthopaedic Foot Club, co-founder of the MGH Foot & Ankle Research and Innovation Lab (FARIL) and has been consistently recognized as one of Castle Connolly Top Doctors® and Boston's Top Doctors.","length":740,"tagName":"p"},{"type":"text","content":"In addition to his clinical practice, Dr. DiGiovanni has published over 250 articles, edited five medical textbooks, and contributed to numerous global innovations in foot and ankle surgery, including FDA-approved technologies. He has served on multiple editorial boards, consulted for athletes from collegiate to Olympic levels, and advised leading orthopedic companies, worldwide.","length":382,"tagName":"p"},{"type":"text","content":""Patient-centric advancements in orthopedic surgery continue to accelerate at a remarkable pace, including contributions specific to the foot and ankle subspecialty," said Dr. DiGiovanni. "Novel absorbable implants represent one of the greatest areas of technological innovation and hold a tremendous promise for patients. Bioretec is at the forefront of surgical device evolution with its novel biocompatible implants, and I look forward to joining the Scientific Advisory Board to help advance these exciting technologies."","length":545,"tagName":"p"},{"type":"text","content":"Bioretec's SAB provides strategic clinical insights as the company advances commercialization of its breakthrough implant platforms, inclu...